The expression of angiotensin-I converting enzyme in human atherosclerotic plaques is not related to the deletion/insertion polymorphism but to the risk of restenosis after coronary interventions

Atherosclerosis

Volumn 130, Issue 1-2, 1997, Pages 203-213

  Haberbosch, Werner ^a,c   Bohle, Rainer M ^a   Franke, Folker E ^a   Danilov, Sergei ^b,d   Alhenc Gelas, Francois ^b   Braun Dullaeus, Rüdiger ^a,e   Hölschermann, Hans ^a   Waas, Wolfgang ^a   Tillmanns, Harald ^a   Gardemann, Andreas ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b INSERM   (France)

^c MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

ACE genotype; ACE phenotype; cellularity; fibrotic plaques; intimal smooth muscle cells

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT; ANGIOPLASTY; ARTICLE; ATHEROSCLEROSIS; BALLOON DILATATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESTENOSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ATHERECTOMY, CORONARY; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; DNA TRANSPOSABLE ELEMENTS; FEMALE; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; RECURRENCE; RISK FACTORS; SEQUENCE DELETION;

EID: 0030888593     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(96)06058-3     Document Type: Article

References (50)

1. Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine: a paradigm shift. Circulation 1994;89:493-498.
2. Naftilan AJ, Ryan TJ, Pratt RE, Dzau VJ. Localization and differential regulation of angiotensinogen mRNA expression in the vessel wall. J Clin Invest 1991;87:1300-1311.
3. Arnal JF, Battle T, Rasetti C, Challah M, Costerousse O, Vicaut E, Michel JB, Alhenc-Gelas F. ACE in three tunicae of rat aorta: expression in smooth muscle and effect of renovascular hypertension. Am J Physiol 1994;267(Heart Circ Physiol 36):H1777-H1784.
4. Battle T, Arnal JF, Challah M, Michel JB. Selective isolation of rat aortic wall layers and their cell types in culture. Application to converting enzyme activity measurement. Tissue and Cell 1994;26:943-955.
5. Morishita R, Gibbons GH, Ellison KE, Lee W, Zhang L, Yu H, Kaneda Y, Ogihara T, Dzau VJ. Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme. J Clin Invest 1994;94:978-984.
6. Fishel RS, Thourani V, Eisenberg SJ, Shai SY, Corson MA, Nabel EG, Bernstein KE, Berk BC. Fibroblast growth factor stimulates angiotensin converting enzyme expression in vascular smooth muscle cells. Possible mediator of the response to vascular injury. J Clin Invest 1995;95:377-387.
7. Naftilan AJ, Pratt RE, Dzau VJ. Induction of platelet-derived growth factor A chain and c-myc gene expression by angiotensin II in cultured rat vascular smooth vessel cells. J Clin Invest 1989;83:1419-1424.
8. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, Tiret PA, Alhenc-Gelas F, Soubrier F. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992;359:641-644.
9. Morris B. Hypothesis: an angiotensin converting enzyme geno-type present in one of three caucasians is associated with an increased mortality rate. Clin Exp Pharm Physiol 1996;23:1-10.
10. Mattu RK, Needham EWA, Galton DJ, Frangos E, Clark AJL, Caulfield MA. DNA variant at the angiotensin-converting enzyme gene locus associates with coronary artery disease in the Caerphilly Heart Study. Circulation 1994; 1:270-274.
11. Nakai K, Itoh C, Miura Y, Hotta K, Musha T, Itoh T, Miyakawa T, Iwasaki R, Hiramori K. Deletion polymorphism of the angiotensin I-converting enzyme is associated with serum ACE concentration and increased risk for CAD in the Japanese. Circulation 1994;90:2199-2202.
12. Lindpaintner K, Pfeffer MA, Kreutz R, Stamper MJ, Grodstein F, LaMotte F, Buring BS, Hennekens H. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. New Engl J Med 1995;2:706-711.
13. Gardemann A, Weiß T, Schwartz O, Eberbach A, Katz N, Hehrlein FW, Tillmanns H, Waas W, Haberbosch W. Gene polymorphism but not catalytic activity of angiotensin I-converting enzyme is associated to coronary artery disease and myocardial infarction in low risk groups. Circulation 1995;2:2796-2799.
14. Cambien F, Costerousse O, Tiret L, Poirier O, Lecerf L, Gonzales MF, Evans A, Arveiler D, Cambou JP, Luc G, Rakotovao R, Ducimetiere P, Soubrier F, Alhenc-Gelas F. Plasma levels and gene polymorphism of angiotensin-converting enzyme in relation to myocardial infarction. Circulation 1994;90:669-676.
15. Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F. Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. Biochem J 1993;90:33-40.
16. Danser AJH, Schalekamp MADH, Bax WA, van den Brink AM, Saxena PR, Riegger GAJ, Schunkert H. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 1995;92:1387-1388.
17. Morell NW, Atochina EN, Morris KG, Danilov SM, Stenmark KR. Angiotensin converting enzyme expression is increased in small pulmonary arteries of rats with hypoxia-induced pulmonary hypertension. J Clin Invest 1995; 96:1823-183.
18. Danilov S, Jaspard E, Churakova T, Towbin H, Savoie F, Wei L, Alhenc-Gelas F. Structure-function analysis of angiotensin I-converting enzyme using monoclonal antibodies. J Biol Chem 1994, 269:26806-26814.
19. Falkenhahn M, Franke FE, Bohle RM, Zhu YC, Stauss HM, Bachmann S, Danilov S, Unger T. Cellular distribution of angiotensin-converting enzyme after myocardial infarction. Hypertension 1995;25:219-226.
20. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, Macdonald S, Pulford KAF, Stein H, Mason DY. Immunoenzymatic labelling of monoclonal anti-alkaline phosphatase (APAAP) complexes. J Histochem Cytochem 1984;32:219-229.
21. Remmele W, Schicketanz K-H. Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (CAIC score) vs. subjective grading (IRS). Pathol Res Pract 1993;189:862-866.
22. Beck T, Weikel W, Brumm C, Wilkens C, Pollow K, Knapstein PG. Immunohistochemical detection of hormone receptors in breast carcinomas (ER-ICA, PgR-ICA): prognostic usefulness and comparison with the biochemical radioactive-ligand binding assay (DCC). Gynecol Oncol 1994;53:220-227.
23. Kawasaki ES. Sample preparation from blood, cells and other fluids. In: Innis MA, Gelfand DH, Snisky JJ, White TJ (EDS). PCR Protocols: A Guide to Methods and Applications. San Diego, Academic Press, 1990;146-152.
24. Campbell-Boswell M, Robertson AL. Effects of angiotensin II and vasopressin on smooth muscle cells in vitro. Exp Mol Pathol 1981;35:265-276.
25. Ross R, Glomset J, Kariya B, Harker LA. Platelet dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci USA 1974;71:1207-1210.
26. Kawahara Y, Sunako M, Tsuda T, Fukuzaki H, Fukumoto Y, Takai Y. Angiotensin II induces expression of the c-fos gene through protein kinase C activation and calcium ion mobilization in cultured vascular smooth muscle cells. Biochem Biophys Res Commun 1988;150:52-59.
27. Muller R, Brovo R, Burckhardt J, Curran T. Induction of c-fos gene and protein by growth factors precedes activation of c-myc. Nature 1984;312:716-720.
28. Gammage MD, Franklyn JA. Role of proto-oncogenes in the control of myocardial growth and function. Clin Sci 1991;80:405-411.
29. Fernandez LA, Twickler J, Mead A. Neovascularization produced by angiotensin II. J Lab Clin Med 1985;105:141-145.
30. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990;15:327-331.
31. Chobanian AV. The effect of ACE inhibitors and other anti-hypertensive drugs on cardiovascular risk factors and atherogenesis. Clin Cardiol 1990;13:VII-43-VII-48.
32. Aberg G, Ferrer P. Effects of captopril on the atherogenesis in cynomologus monkeys. J Cardiovasc Pharmacol 1990;15:S65-S72.
33. Rolland PH, Charpiot P. Friggi A, Piquet P, Barlatier A, Scalbert E, Bodard H, Tranier P, Mercier C, Luccioni R, Garcon D. Effects of angiotensin-converting enzyme inhibition with perindolol on hemodynamics, arterial structure, and wall rheology in the hindquaters of atherosclerotic mini-pigs. Am J Cardiol 1993;71:22E-27E.
34. Powell JS, Clozel JP, Muller RKM, Kuhn H, Hefti F, Hosang M, Baumgartner HR. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989;245:186-188.
35. Fingerle J, Müller RMK, Kuhn H, Pech M, Baumgartner HR. Mechanism of inhibition of neointimal formation by the angiotensin-converting enzyme inhibitor cilazapril. Arterioscler Thromb Vasc Biol 1995;15:1945-1950.
36. Michel JB, Plissonier D, Bruneval P. Effect of perindopril on the immune arterial wall remodelling in the rat model of arterial graft rejection. Am J Med 1992;92(Suppl 4B):39S-46S.
37. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-1346.
38. Topol EJ, Leya F, Pinkerton CA, Whitlow PL, Hofling B, Simonton CA, Masden RR, Serruys PW, Leon MB, Williams DO, King SB, Mark DB, Isner JM, Holmes DR, Ellis SG, Lee KL, Keeler GP, Berdan LG, Hinohara T, Califf RM. The CAVEAT Study Group. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. New Engl J Med 1993;329;221-227.
39. Samani NJ, Martin DS, Brack M, Cullen J, Chauhan A, Lodwick D, Harley A, Swales JD, deBono DP, Gershlick AH. Insertion/deletion polymorphism in the angiotensin-converting enzyme gene and risk of restenosis after coronary angioplasty. Lancet 1995;345:1013-1016.
40. Hamon M, Bauters C, Amant C, McFadden EP, Helbecque N, Lablanche J-M, Bertrand ME, Amouyel P. Relation between the deletion polymorphism of the angiotensin-converting enzyme and late luminal narrowing after coronary angioplasty. Circulation 1995;92:296-299.
41. Ohishi M, Fujii K, Minamino T, Higaki J, Kamitani A, Rakugi H, Zhao Y, Mikami H, Miki T, Ogihara T. A potent genetic risk factor for restenosis. Nat Genet 1993;5:324-325.
42. Rakugi H, Kim D-K, Krieger JE, Wang DS, Dzau VJ, Pratt RE. Induction of angiotensin converting enzyme in the neointima after vascular injury. Possible role in restenosis. J Clin Invest 1994;93:339-346.
43. Rakugi H, Wang DS, Dzau VJ, Pratt RE. Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation. Circulation 1994;90:449-455.
44. Zambetis-Bellesis M, Dusting GJ, Mendelsohn FA, Richardson K. Autoradiographic localization of angiotensin-converting enzyme and angiotensin II binding sites in early atheroma-like lesions in rabbit arteries. Clin Exp Pharmacol Physiol 1991;18:337-340.
45. Chumachemko P, Andreeva YU, Zhdanov V, Osborne-Peliegrin M, Danilov S. Expression of angiotensin-converting enzyme in atherosclerotic plaques of human arteries. Atherosclerosis 1995;115 (Suppl):S63(Abstract).
46. Dubey RK, Jackson EK, Lüscher TF. Nitric Oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. J Clin Invest 1995;96:141-149.
47. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cell response to angiotensin II. J Clin Invest 1993;91:2268-2274.
48. Bennett PH. The diagnosis of diabetes:New international classification and diagnostic criteria. Annu Rev Med 1983;34:295-309.
49. Bohle RM, Nüsse T, Dreyer T, Haberbosch W, Danilov S, Frauke FE. Cardiac Augivteusin I converting enzyme (ACE) expression in hypertrophic heart disease and sudden cardiac death. Path Res Pract 1995;191:624 (Abstract).
50. Metiger R, Bohle RM, Alheuc-Gelas F, Danilov S, Frauke FE. Augivteusin I converting enzyme (ACE) in atherosclesotic plaques. Path Res Pract 1996;192:364 (Abstract).